PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Early Best Available Therapy Cuts Mortality in 3GCRE, Not Clearly in CR-GNB

3GCRECRECRAcarbapenemspolymyxinscolistinceftazidime-avibactamsulbactammultidrug-resistant Gram-negative bacteriabloodstream infectiontarget trial emulationantimicrobial stewardshiptime to appropriate therapyantimicrobial resistance Infectious Disease / Antimicrobials

Background Information

Timely antibiotics cut mortality in drug-resistant bacterial infections.

Timely appropriate antibiotics are crucial for managing multidrug-resistant Gram-negative bloodstream infections, yet their impact remains uncertain. Early best available therapy reduced 14-day mortality in 3rd-generation cephalosporin-resistant Enterobacterales infections by 7.4%, but results were unclear for carbapenem-resistant strains. The study suggests benefits of early appropriate therapy in certain infections, highlighting the need for optimized antimicrobial strategies particularly with high resistance settings. Early best available therapy reduces mortality in some multidrug-resistant Gram-negative bloodstream infections but may not suffice for all cases.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Mezzadri L, Tan WC, Hao X, Quah J, Manesh A, Chang YT, Nguyen ATK, Ding Y, Kitsaran S, Chua HH, Bory S, Ponnampalavanar S, Anunnatsiri S, Mazlan MZ, Dhiloo AK, Plongla R, Lay-Hoon Kwa A, Mahmood SF, Roman AD, Thwaites CL, Tho PV, Wu S, Chotiprasitsakul D, Wong KJ, Wijaya H, Abad CL, Rehman Khalid MO, Salahuddin Mamun GM, Rajahram GS, Gutierres H, Hon HN, Van Giang T, Pham NT, Karkey A, Gunasekara S, Hamers RL, Sinto R, Lubis IND, Wang M, Moni M, Liu PY, Xiao Y, Khanal B, Priya NL, Doi Y, Honda H, Baljin B, Gurav U, Asli R, Ling L, Dhungana A, Hsu LY, Paterson DL, Mo Y, ACORN-HAI investigators

Citation: Mezzadri L, Tan WC, Hao X, et al. Early best available antibiotic therapy for multidrug-resistant gram-negative bloodstream infections: a target trial emulation. EClinicalMedicine. 2026;101:104302. doi:10.1016/j.eclinm.2026.104302

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.